Press room

25th February 2020
Cambridge and Leeds, UK, 25th February 2020: Domainex Ltd., a fully integrated provider of drug discovery services from its Medicines Research Centre near Cambridge, UK, has entered into a research partnership with LUNAC Therap
13th February 2020
Cambridge, UK, 13th February 2020 / Domainex Ltd is pleased to announce the appointment of Dr Tom Mander as Chief Executive Officer. Dr Mander will  take over when Dr Trevor Perrior retires from the role in April 2020.
23rd January 2020
Saffron Walden, UK, 23 January 2020/ Domainex Ltd. is very pleased to announce that it has received accreditation from the French Ministry of Higher Education, Research and Innovation for a period of three years.
26th April 2019
Today (26th April 2019), Medicines Discovery Catapult announces the launch of twenty-two partnerships with UK contract research organisations (CROs).
28th March 2019
20th March 2019
Saffron Walden, UK,  and Basel, Switzerland 20 March 2019 / Domainex Ltd, an integrated provider of drug discovery services that has established a world-leading position in fragment-based drug discovery and
7th March 2019
London and Saffron Walden, UK, 7th March 2019 Domainex is pleased to announce that a team of its scientists, working in close partnership with Professor Michael Schneider and his team at Imperial College, have found a potential new drug for treating the heart damage caused by a h
20th December 2018
A collaboration between St George's, University of London and Domainex has resulted in several publications. The most recent, published in the September 2018 issue of Molecular Pharmacology, has been featured on the front cover of the journal.   
20th December 2018
DMXD-011  is an orally-bioavailable and selective inhibitor of TBK1 and IKK-epsilon, invented by Domainex, that is presently in pre-clinical development.
20th December 2018
The results of a productive collaboration between Domainex and Oxford University have been published in a recent Nature Communications paper titled "Small molecule inhibitors of RAS-effector protein interactions derived using an intrace